NVCR - NovoCure Limited
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$33.50
DETAILS
HIGH:
$47.00
LOW:
$20.00
MEDIAN:
$33.50
CONSENSUS:
$33.50
UPSIDE:
86.53%
About NovoCure Limited (https://www.novocure.com)
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optune Lua for the treatment of malignant pleural mesothelioma. The company also has ongoing or completed clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| William F. Doyle | Executive Chairman | 1962 | $1,777,965 USD |
| Christoph Brackmann | Chief Financial Officer | 1974 | $1,162,387 USD |
| Uri Weinberg | Chief Innovation Officer & Chief Medical Officer | 1979 | $1,158,934 USD |
| Frank Leonard | Chief Executive Officer | – | $974,316 USD |
| Mukund Paravasthu | Chief Operating Officer | 1970 | $965,560 USD |
| Michael Puri | Chief Human Resources Officer | 1969 | $932,882 USD |
| Barak Ben Arye | General Counsel | 1977 | $796,075 USD |
| Adam Daney | Head of Investor Relations | – | – |